Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma.

摘要: Metastatic melanoma has benefited from immunotherapy and targeted therapy advances. Faced with the inescapable onset of treatment resistance, choice a second-line can be guided by patient-derived tumor xenograft (PDTX). This new approach requires an excellent multidisciplinary collaboration where surgeon key role to play. Each patient included (stage IIIC or IV) presented subcutaneous metastasis that could surgically resected. The performed orthotopic PDTX on CB17-SCID mice. To validate model, material was amplified over three successive generations animals obtain cohorts compatible carrying out study compare response (vemurafenib versus controls). Tumors were characterized (histologically genetically) at all stages generations' amplification. Functional imaging fluorine-18 fluorodeoxyglucose PET scan for third generation PDTX. Seventeen patients mutated BRAF V600E included, yielding 257 Clinical, histological, genetic characteristics grafted tumors stable mice generations. vemurafenib observed evidenced decreased in glucose uptake treated tumors. models are being widely used fundamental research more clinical issues. If simple easily reproducible metastatic melanoma, organized platform is essential implement them. In our experience, surgeons have play cohesion this therapeutic approach.